免疫腫瘍学診断市場 - エグゼクティブ/コンサルタントガイドとカスタマイズ予測/分析付き（2024年～2028年）

診断、特にコンパニオン診断が免疫腫瘍学治療の成功を牽引しています。診断薬業界は、全く新しいセグメントを生み出しつつあります。それも小さな分野ではありません。飛躍的な成長が約束されています。組織学、ゲノミクス、リキッドバイオプシーが融合しつつあり、製薬会社、診断会社、機器サプライヤーの複雑なネットワークが、がんを克服するための新たなアプローチでしのぎを削っています。

がん治療における革命が進行中です。身体の自然な免疫防御を利用した新しい治療法は、前例のない成功を収めています。しかし、適切な治療法を選択するための診断法、特にバイオマーカーが切実に求められています。

当レポートは、世界の免疫腫瘍学診断市場について調査し、市場の概要とともに、用途別、技術別、顧客別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 市場ガイド

第2章 イントロダクションと市場定義

• 免疫腫瘍学診断とは何か
• 免疫腫瘍学- 迫りくる治療法
• 市場の定義
• 調査手法
• 視点：ヘルスケアとIVD業界

第3章 免疫療法- 免疫技術ガイド

• 免疫システム
• 免疫腫瘍学診断

第4章 業界の概要

• 市場参入組織
  • 学術研究機関
  • 診断試験開発者
  • 計装サプライヤー
  • 薬品・試薬メーカー
  • 病理サプライヤー
  • 独立系臨床検査室
  • 国立/地域研究所
  • 病院検査室
  • 臨床検査室
  • 監査機関
  • 認証機関

第5章 市場動向

• 成長促進要因
• 成長抑制要因
• 診断技術開発

第6章 がん免疫腫瘍学診断の最近の進歩

第7章 主要企業のプロファイル

• 10x Genomics, Inc.
• Abbott Laboratories
• AccuraGen Inc.
• Adaptive Biotechnologies
• Aethlon Medical
• Agilent
• Anchor Dx
• ANGLE plc
• ARUP Laboratories
• AVIVA Systems Biology
• Baylor Miraca Genetics Laboratories
• Beckman Coulter Diagnostics（Danaher）
• Becton, Dickinson and Company
• Berkley Lights
• BGI Genomics Co. Ltd
• Bioarray Genetics
• Biocartis
• Biocept, Inc.
• Biodesix Inc.
• BioFluidica
• BioGenex
• BioIVT
• Biolidics Ltd
• bioMerieux Diagnostics
• Bioneer Corporation
• Bio-Rad Laboratories, Inc.
• Bio-Reference Laboratories
• Bio-Techne
• Bioview
• Bristol-Myers Squibb
• Burning Rock
• Cardiff Oncology
• Caris Molecular Diagnostics
• Castle Biosciences, Inc.
• CellCarta
• CellMax Life
• Cepheid（Danaher）
• Charles River Laboratories
• Circulogene
• Cizzle Biotech
• Clearbridge Biomedics
• Clinical Genomics
• Cytolumina Technologies Corp.
• Datar Cancer Genetics Limited
• Diagnologix LLC
• Diasorin S.p.A.
• Dxcover
• Element Biosciences
• Enzo Biochem
• Epic Sciences
• Epigenomics AG
• Eurofins Scientific
• Fabric Genomics
• Fluxion Biosciences（Cell Microsystems）
• Freenome
• FUJIFILM Wako Diagnostics
• Fujirebio
• Fyr Diagnostics
• GeneFirst Ltd.
• Genetron Holdings
• GenomOncology
• GILUPI Nanomedizin
• Guardant Health
• HansaBiomed
• HTG Molecular Diagnostics
• iCellate
• ICON PLC
• Illumina
• Incell Dx
• Inivata
• INOVIQ
• Invitae Corporation
• Invivogen
• Invivoscribe
• J&J Innovative Medicine
• KEW
• Lucence Health
• Lunglife AI Inc
• MDNA Life SCIENCES, Inc.
• MDx Health
• Menarini Silicon Biosystems
• Mesa Laboratories, Inc.
• Millipore Sigma
• Miltenyi Biotec
• miR Scientific
• Myriad Genetics
• Nanostring
• NantHealth, Inc.
• Natera
• NeoGenomics
• NGeneBio
• Novogene
• Oncimmune
• Oncocyte
• OncoDNA
• Oncohost
• Oxford Nanopore Technologies
• PamGene
• Panagene
• Personalis
• PGDx（Labcorp）
• Precipio
• PrecisionMed
• Predicine
• Predictive Oncology
• Prenetics
• Promega
• Qiagen
• QuidelOrtho
• Rarecells SAS
• RareCyte
• Recursion Pharma
• Revvity
• Roche Diagnostics
• Screencell
• Sherlock Biosciences
• Siemens Healthineers
• simfo GmbH
• Singlera Genomics Inc.
• Singular Genomics
• Singulomics
• SkylineDx
• Standard BioTools
• Stilla Technologies
• Sysmex Inostics
• Tempus Labs, Inc.
• Thermo Fisher Scientific
• Todos Medical
• Ultima Genomics
• Veracyte
• VolitionRX
• Vortex Biosciences

第8章 免疫腫瘍学診断の世界市場

• 国別世界市場概要
• アッセイタイプ別世界市場概要
• 技術別世界市場概要
• 顧客別世界市場概要

第9章 世界の免疫腫瘍学診断市場：用途別

• チェックポイント
• サイトカイン
• 生殖細胞遺伝学
• 遺伝性腫瘍
• 腫瘍微小環境
• その他

第10章 世界の免疫腫瘍学診断市場：技術別

• 次世代シーケンシング
• PCR
• FISH/IHC
• 化学/IA
• その他

第11章 世界の免疫腫瘍学診断市場：顧客別

• 製薬会社
• 診療所
• その他

第12章 付録

Table of Tables

• Table 1: List of Cancers by Mortality
• Table 2: Overview of Innate and Adaptive Immunity
• Table 3: FDA Approved Monoclonal Antibodies in Cancer treatment
• Table 4: FDA Approved Companion diagnostics in Cancer treatment
• Table 5: Market Players by Type
• Table 6: Five Factors Driving Growth
• Table 7: Three Factors Limiting Growth
• Table 8: Global Market by Region
• Table 9: Global Market by Assay Type
• Table 10: Global Market by Technology
• Table 11: Global Market by Customer
• Table 12: Checkpoint by Country
• Table 13: Cytokine by Country
• Table 14: Germline Genetic by Country
• Table 15: Genetic Tumor by Country
• Table 16: Tumor Microenvironment by Country
• Table 17: Other by Country
• Table 18: NGS by Country
• Table 19: PCR by Country
• Table 20: Fish/IHC by Country
• Table 21: Chem/IA by Country
• Table 22: Other Technology by Country
• Table 23: Pharma by Country
• Table 24: Clinic by Country
• Table 25: Other Customer by Country
• Table 26: The Most Common Assays
• Table 27: Largest Revenue Assays
• Table 28: Clinical Lab Fee Schedule

Table of Figures

• Figure 1: Cancer Death Rates-USA, CDC
• Figure 2: Global healthcare Spending
• Figure 3: The Lab Test Pie
• Figure 4: Helper T Cell Roles
• Figure 5: Antibody Diagram
• Figure 6: Macrophages attack a Cancer Cell
• Figure 7: The Tumour Micro Environment
• Figure 8: The Road to Diagnostics
• Figure 9: Comparing IO Diagnostic and Traditional Testing
• Figure 10: Growth rates of IO DiagnosticTechnologies
• Figure 11: Global Market Density Chart
• Figure 12: Global Market by Assay Type-Base vs. Final
• Figure 13: Global Market by Assay Type Base Year
• Figure 14: Global Market by Assay Type End Year
• Figure 15: Assay Type Share by Year
• Figure 16: Assay Type Segments Growth
• Figure 17: Global Market by Technology-Base vs. Final
• Figure 18: Global Market by Technology Base Year
• Figure 19: Global Market by Technology End Year
• Figure 20: Technology Share by Year
• Figure 21: Technology Segments Growth
• Figure 22: Global Market by Customer-Base vs. Final
• Figure 23: Global Market by Customer Base Year
• Figure 24: Global Market by Customer End Year
• Figure 25: Customer Share by Year
• Figure 26: Customer Segments Growth
• Figure 27: Checkpoint Growth
• Figure 28: Cytokine Growth
• Figure 29: Germline Genetic Growth
• Figure 30: Genetic Tumor Growth
• Figure 31: Tumor Microenvironment Growth
• Figure 32: Other Growth
• Figure 33: NGS Growth
• Figure 34: PCR Growth
• Figure 35: Fish/IHC Growth
• Figure 36: Chem/IA Growth
• Figure 37: Other Technology Growth
• Figure 38: Pharma Growth
• Figure 39: Clinic Growth
• Figure 40: Other Customer Growth
• Figure 41: Prevalence of Cancer Treatments
• Figure 42: IVD Test Menu Growth
• Figure 43: IVD Test Average Fees-A Ten Year View

OVERVIEW:

Diagnostics, companion diagnostics, is driving the success of Immuno-oncology Therapeutics. An entire new segment of the diagnostics industry is being created. And its not a small segment either. It promises to grow dramatically. Histology, genomics and liquid biopsy are converging. A complicated network of pharmaceutical companies, diagnostic companies and instrumentation suppliers are jockeying for position in a new approach to conquering cancer. The approach seems to be working and showing great promise.

A revolution in cancer therapy is underway. New therapy based on using the body's natural immune defenses is having unprecedented success. But diagnostics, especially biomarkers are desperately needed to help select the right therapy.

The technology is moving faster than the market. The impact on the health care industry is enormous. Tumor Mutational Burden? Checkpoint Inhibitors? Cytokines? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size in this new expanded and comprehensive report.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

• B.Sc. (Chemistry) University of BC
• M.B.A. (Finance and Policy) University of BC
• Market Research Seminar - Burke Institute
• Finance for Senior Executives - Harvard Business School

Table of Contents

1. Market Guides

• 1.1. Situation Analysis
• 1.2. Guide for Executives and Marketing Staff
• 1.3. Guide for Investment Analysts and Management Consultants

2. Introduction and Market Definition

• 2.1. What are Immuno-Oncology Diagnostics?
• 2.2. Immuno-oncology-the looming cure
  • 2.2.1. Immuno-oncology Diagnostics Takes a Leading Role
• 2.3. Market Definition
  • 2.3.1. Market Size
  • 2.3.2. Currency
  • 2.3.3. Years
• 2.4. Methodology
  • 2.4.1. Methodology
  • 2.4.2. Sources
  • 2.4.3. Authors
• 2.5. Perspective: Healthcare and the IVD Industry
  • 2.5.1. Global Healthcare Spending
  • 2.5.2. Spending on Diagnostics
  • 2.5.3. Important Role of Insurance for Diagnostics

3. Immunotherapy-Guide to Immune Technologies

• 3.1. The Immune System
  • 3.1.1. Innate immune system
    • 3.1.1.1. Surface barriers
    • 3.1.1.2. Inflammation
    • 3.1.1.3. Complement system
    • 3.1.1.4. Cellular barriers
    • 3.1.1.5. Natural killer cells
  • 3.1.2. Adaptive immune system
    • 3.1.2.1. Lymphocytes
    • 3.1.2.2. Killer T cells
    • 3.1.2.3. Helper T cells
    • 3.1.2.4. Gamma delta T cells
    • 3.1.2.5. B lymphocytes and antibodies
  • 3.1.3. Tumor immunology-the immune surveillance system
• 3.2. Immuno Oncology Diagnostics
  • 3.2.1. Checkpoint Assays
    • 3.2.1.1. Outlook for Checkpoint Assays
  • 3.2.2. Cytokine Assays
    • 3.2.2.1. Outlook for Cytokine Assays
  • 3.2.3. Genomic Germline
    • 3.2.3.1. Outlook for Genomic Germline
  • 3.2.4. Genomic Tumour
    • 3.2.4.1. Outlook for Genomic Tumour
  • 3.2.5. Tumor Microenviroment
    • 3.2.5.1. Outlook for Tumor Microenvironment
  • 3.2.6. Others
    • 3.2.6.1. Outlook for Other Diagnostics

4. Industry Overview

• 4.1. Players in a Dynamic Market
  • 4.1.1. Academic Research Lab
  • 4.1.2. Diagnostic Test Developer
  • 4.1.3. Instrumentation Supplier
  • 4.1.4. Chemical/Reagent Supplier
  • 4.1.5. Pathology Supplier
  • 4.1.6. Independent Clinical Laboratory
  • 4.1.7. Public National/regional Laboratory
  • 4.1.8. Hospital Laboratory
  • 4.1.9. Physicians Office Lab (POLS)
  • 4.1.10. Audit Body
  • 4.1.11. Certification Body

5. Market Trends

• 5.1. Factors Driving Growth
  • 5.1.1. Outcome potential
  • 5.1.2. Companion Diagnostics
  • 5.1.3. Funding
  • 5.1.4. Technology Environment
  • 5.1.5. Target Solutions
• 5.2. Factors Limiting Growth
  • 5.2.1. Complex Role of Diagnostics
  • 5.2.2. Clinical Trials Role
  • 5.2.3. Protocols
• 5.3. Diagnostic Technology Development
  • 5.3.1. Combinations-Issues and Complexity
  • 5.3.2. Shifting Role of Diagnostics
  • 5.3.3. Multiplexing and Foundation One
  • 5.3.4. The Disruption Dynamic
  • 5.3.5. The Race for Biomarkers
  • 5.3.6. The Next Five Years

6. Cancer Immuno-Oncology Diagnostics Recent Developments

• 6.1. Recent Developments-Importance and How to Use This Section
  • 6.1.1. Importance of These Developments
  • 6.1.2. How to Use This Section
• 6.2. Thermo Fisher and Bayer to Develop CDx for Cancer Therapies
• 6.3. ClearNote Health Expands Into Immunotherapy Monitoring
• 6.4. Foundation Medicine to Collaborate on CDx for Lung Cancer
• 6.5. Qiagen and Myriad Genetics Partner to Develop Cancer CDx
• 6.6. Lung Cancer Data Heralds Shift for Hummingbird Dx
• 6.7. PamGene Awarded Euro-7.5M for Immunotherapy Test
• 6.8. Freenome Acquires Oncimmune
• 6.9. Guardant Health Gets Coverage for Liquid Biopsy Treatment Response Test
• 6.10. BostonGene to Develop Sarcoma-Specific Liquid Biopsy
• 6.11. Exact Sciences OncoExTra Therapy Selection Test
• 6.12. Integrated DNA Technologies Buys NGS Research Assays
• 6.13. Navignostics Using Single-Cell Spatial Proteomics
• 6.14. New Reference Samples for NGS-Based Cancer Tests
• 6.15. Spatial Proteomics Panel for Immuno-Oncology
• 6.16. dMMR, MSI Assays for Immunotherapy Patient Selection
• 6.17. OncoHost Expands Prophet Platform Research
• 6.18. Protein-Based Liquid Biopsy Panel Assesses TME
• 6.19. Oncimmune Announces Sixfold Revenue Increase
• 6.20. Mayo Clinic, Personalis Ink Collaboration
• 6.21. Lucence Liquid Biopsy Test Tracks Immune Treatment ctDNA Changes
• 6.22. Qiagen, OncXerna Close Companion Dx Development Deal
• 6.23. Natera Test to Guide Therapy for Bladder Cancer
• 6.24. Veracyte Halio Acquisition to Boost Immuno-oncology Activity
• 6.25. Freenome Eyes New Dx Possibilities
• 6.26. Oncocyte Data has Potential as Immunotherapy Response Predictor
• 6.27. OncoDNA use HalioDx to Expand into North America
• 6.28. Adaptive Biotechnologies, Q2 Solutions Agreement for ImmunoSeq Assay
• 6.29. Qiagen Expands Immuno-Oncology Portfolio
• 6.30. Immune Profiling System Redirected to Fight COVID-19
• 6.31. IncellDx Awarded PD-L1 Detection Patent
• 6.32. FDA Approves CDx for Trastuzumab
• 6.33. Promega Nabs CE Mark for Microsatellite Instability IVD
• 6.34. ArcherDx partners with AstraZeneca for Immuno-Oncology
• 6.35. Germline Results Guides Precision Therapy
• 6.36. Agilent PD-L1 Assay Gets FDA Approval
• 6.37. Bayer, OrigiMed Form Companion Diagnostic Development Alliance
• 6.38. Bio-Me to Develop Microbiome Biomarker Test for Cancer Immunotherapy
• 6.39. SkylineDx, BioInvent Collaborate to Characterize Predictive Immunological Signatures
• 6.40. Biocare Medical Launches 7 Novel IVD Antibodies

7. Profiles of Key Immuno-oncology Companies

• 7.1 10x Genomics, Inc.
• 7.2. Abbott Laboratories
• 7.3. AccuraGen Inc.
• 7.4. Adaptive Biotechnologies
• 7.5. Aethlon Medical
• 7.6. Agilent
• 7.7. Anchor Dx
• 7.8. ANGLE plc
• 7.9. ARUP Laboratories
• 7.10. AVIVA Systems Biology
• 7.11. Baylor Miraca Genetics Laboratories
• 7.12. Beckman Coulter Diagnostics (Danaher)
• 7.13. Becton, Dickinson and Company
• 7.14. Berkley Lights
• 7.15. BGI Genomics Co. Ltd
• 7.16. Bioarray Genetics
• 7.17. Biocartis
• 7.18. Biocept, Inc.
• 7.19. Biodesix Inc.
• 7.20. BioFluidica
• 7.21. BioGenex
• 7.22. BioIVT
• 7.23. Biolidics Ltd
• 7.24. bioMerieux Diagnostics
• 7.25. Bioneer Corporation
• 7.26. Bio-Rad Laboratories, Inc.
• 7.27. Bio-Reference Laboratories
• 7.28. Bio-Techne
• 7.29. Bioview
• 7.30. Bristol-Myers Squibb
• 7.31. Burning Rock
• 7.32. Cardiff Oncology
• 7.33. Caris Molecular Diagnostics
• 7.34. Castle Biosciences, Inc.
• 7.35. CellCarta
• 7.36. CellMax Life
• 7.37. Cepheid (Danaher)
• 7.38. Charles River Laboratories
• 7.39. Circulogene
• 7.40. Cizzle Biotech
• 7.41. Clearbridge Biomedics
• 7.42. Clinical Genomics
• 7.43. Cytolumina Technologies Corp.
• 7.44. Datar Cancer Genetics Limited
• 7.45. Diagnologix LLC
• 7.46. Diasorin S.p.A.
• 7.47. Dxcover
• 7.48. Element Biosciences
• 7.49. Enzo Biochem
• 7.50. Epic Sciences
• 7.51. Epigenomics AG
• 7.52. Eurofins Scientific
• 7.53. Fabric Genomics
• 7.54. Fluxion Biosciences (Cell Microsystems)
• 7.55. Freenome
• 7.56. FUJIFILM Wako Diagnostics
• 7.57. Fujirebio
• 7.58. Fyr Diagnostics
• 7.59. GeneFirst Ltd.
• 7.60. Genetron Holdings
• 7.61. GenomOncology
• 7.62. GILUPI Nanomedizin
• 7.63. Guardant Health
• 7.64. HansaBiomed
• 7.65. HTG Molecular Diagnostics
• 7.66. iCellate
• 7.67. ICON PLC
• 7.68. Illumina
• 7.69. Incell Dx
• 7.70. Inivata
• 7.71. INOVIQ
• 7.72. Invitae Corporation
• 7.73. Invivogen
• 7.74. Invivoscribe
• 7.75. J&J Innovative Medicine
• 7.76. KEW
• 7.77. Lucence Health
• 7.78. Lunglife AI Inc
• 7.79. MDNA Life SCIENCES, Inc.
• 7.80. MDx Health
• 7.81. Menarini Silicon Biosystems
• 7.82. Mesa Laboratories, Inc.
• 7.83. Millipore Sigma
• 7.84. Miltenyi Biotec
• 7.85. miR Scientific
• 7.86. Myriad Genetics
• 7.87. Nanostring
• 7.88. NantHealth, Inc.
• 7.89. Natera
• 7.90. NeoGenomics
• 7.91. NGeneBio
• 7.92. Novogene
• 7.93. Oncimmune
• 7.94. Oncocyte
• 7.95. OncoDNA
• 7.96. Oncohost
• 7.97. Oxford Nanopore Technologies
• 7.98. PamGene
• 7.99. Panagene
• 7.100. Personalis
• 7.101. PGDx (Labcorp)
• 7.102. Precipio
• 7.103. PrecisionMed
• 7.104. Predicine
• 7.105. Predictive Oncology
• 7.106. Prenetics
• 7.107. Promega
• 7.108. Qiagen
• 7.109. QuidelOrtho
• 7.110. Rarecells SAS
• 7.111. RareCyte
• 7.112. Recursion Pharma
• 7.113. Revvity
• 7.114. Roche Diagnostics
• 7.115. Screencell
• 7.116. Sherlock Biosciences
• 7.117. Siemens Healthineers
• 7.118. simfo GmbH
• 7.119. Singlera Genomics Inc.
• 7.120. Singular Genomics
• 7.121. Singulomics
• 7.122. SkylineDx
• 7.123. Standard BioTools
• 7.124. Stilla Technologies
• 7.125. Sysmex Inostics
• 7.126. Tempus Labs, Inc.
• 7.127. Thermo Fisher Scientific
• 7.128. Todos Medical
• 7.129. Ultima Genomics
• 7.130. Veracyte
• 7.131. VolitionRX
• 7.132. Vortex Biosciences

8. The Global Market for Immuno-Oncology Diagnostics

• 8.1. Global Market Overview by Country
  • 8.1.1. Table-Global Market by Country
  • 8.1.2. Chart-Global Market by Country
• 8.2. Global Market by Assay Type-Overview
  • 8.2.1. Table-Global Market by Assay Type
  • 8.2.2. Chart-Global Market by Assay Type-Base/Final Year Comparison
  • 8.2.3. Chart-Global Market by Assay Type-Base Year
  • 8.2.4. Chart-Global Market by Assay Type-End Year
  • 8.2.5. Chart-Global Market by Assay Type-Share by Year
  • 8.2.6. Chart-Global Market by Assay Type-Segments Growth
• 8.3. Global Market by Technology-Overview
  • 8.3.1. Table-Global Market by Technology
  • 8.3.2. Chart-Global Market by Technology-Base/Final Year Comparison
  • 8.3.3. Chart-Global Market by Technology-Base Year
  • 8.3.4. Chart-Global Market by Technology-End Year
  • 8.3.5. Chart-Global Market by Technology-Share by Year
  • 8.3.6. Chart-Global Market by Technology-Segments Growth
• 8.4. Global Market by Customer-Overview
  • 8.4.1. Table-Global Market by Customer
  • 8.4.2. Chart-Global Market by Customer-Base/Final Year Comparison
  • 8.4.3. Chart-Global Market by Customer-Base Year
  • 8.4.4. Chart-Global Market by Customer-End Year
  • 8.4.5. Chart-Global Market by Customer-Share by Year
  • 8.4.6. Chart-Global Market by Customer-Segments Growth

9. Global Immuno-Oncology Diagnostic Markets-By Application

• 9.1. Checkpoint
  • 9.1.1. Table Checkpoint-by Country
  • 9.1.2. Chart-Checkpoint Growth
• 9.2. Cytokine
  • 9.2.1. Table Cytokine-by Country
  • 9.2.2. Chart-Cytokine Growth
• 9.3. Germline Genetic
  • 9.3.1. Table Germline Genetic-by Country
  • 9.3.2. Chart-Germline Genetic Growth
• 9.4. Genetic Tumor
  • 9.4.1. Table Genetic Tumor-by Country
  • 9.4.2. Chart-Genetic Tumor Growth
• 9.5. Tumor Microenvironment
  • 9.5.1. Table Tumor Microenvironment-by Country
  • 9.5.2. Chart-Tumor Microenvironment Growth
• 9.6. Other
  • 9.6.1. Table Other-by Country
  • 9.6.2. Chart-Other Growth

10. Global Immuno-Oncology Diagnostic Markets-By Technology

• 10.1. NGS
  • 10.1.1. Table NGS-by Country
  • 10.1.2. Chart-NGS Growth
• 10.2. PCR
  • 10.2.1. Table PCR-by Country
  • 10.2.2. Chart-PCR Growth
• 10.3. Fish/IHC
  • 10.3.1. Table Fish/IHC-by Country
  • 10.3.2. Chart-Fish/IHC Growth
• 10.4. Chem/IA
  • 10.4.1. Table Chem/IA-by Country
  • 10.4.2. Chart-Chem/IA Growth
• 10.5. Other Technology
  • 10.5.1. Table Other Technology-by Country
  • 10.5.2. Chart-Other Technology Growth

11. Global Immuno-Oncology Diagnostic Markets-By Customer

• 11.1. Pharma
  • 11.1.1. Table Pharma-by Country
  • 11.1.2. Chart-Pharma Growth
• 11.2. Clinic
  • 11.2.1. Table Clinic-by Country
  • 11.2.2. Chart-Clinic Growth
• 11.3. Other Customer Genetic
  • 11.3.1. Table Other Customer-by Country
  • 11.3.2. Chart-Other Customer Growth

12. Appendices

• 12.1. Prevalence of Cancer Treatments
• 12.2. Growth of Approved IVD Test Menu
• 12.3. Growth of Approved Average IVD Test Fee
• 12.4. The Most Used IVD Assays
• 12.5. The Highest Grossing Assays
• 12.6. Laboratory Fees Schedule